ERBB2 and prostate carcinoma: In prostate cancer, HER2 overexpression activates key signaling pathways, including PI3K/AKT and MAPK/ERK, which promote tumor cell proliferation, survival, and resistance to androgen deprivation therapy (ADT) (7, 8).